PROGNOSTIC VALUE OF A POLYGENIC RISK SCORE FOR CORONARY HEART DISEASE IN INDIVIDUALS AGED 70 YEARS AND OLDER

Johannes T. Neumann, MD, MCR*; Moeen Riaz, PhD*; Andrew Bakshi, PhD; Galina Polekhina, PhD; Le T.P. Thao, PhD; Mark R. Nelson, PhD; Robyn L. Woods, PhD; Gad Abraham, PhD; Michael Inouye, PhD; Christopher M. Reid, PhD; Andrew M. Tonkin, MD; John McNeil, PhD; Paul Lacaze, PhD

BACKGROUND: The use of a polygenic risk score (PRS) to improve risk prediction of coronary heart disease (CHD) events has been demonstrated to have clinical utility in the general adult population. However, the prognostic value of a PRS for CHD has not been examined specifically in older populations of individuals aged ≥70 years, who comprise a distinct high-risk subgroup. The objective of this study was to evaluate the predictive value of a PRS for incident CHD events in a prospective cohort of older individuals without a history of cardiovascular events.

METHODS: We used data from 12,792 genotyped, healthy older individuals enrolled into the ASPREE trial (Aspirin in Reducing Events in the Elderly), a randomized double-blind placebo-controlled clinical trial investigating the effect of daily 100 mg aspirin on disability-free survival. Participants had no previous history of diagnosed atherothrombotic cardiovascular events, dementia, or persistent physical disability at enrollment. We calculated a PRS (meta-genomic risk score) consisting of 1.7 million genetic variants. The primary outcome was a composite of incident myocardial infarction or CHD death over 5 years.

RESULTS: At baseline, the median population age was 73.9 years, and 54.9% were female. In total, 254 incident CHD events occurred. When the PRS was added to conventional risk factors, it was independently associated with CHD (hazard ratio, 1.24 [95% CI, 1.08–1.42], P = 0.002). The area under the curve of the conventional model was 70.53 (95% CI, 67.00–74.06), and after inclusion of the PRS increased to 71.78 (95% CI, 68.32–75.24, P = 0.019), demonstrating improved prediction. Reclassification was also improved, as the continuous net reclassification index after adding PRS to the conventional model was 0.25 (95% CI, 0.15–0.28).

CONCLUSION: A PRS for CHD performs well in older people and improves prediction over conventional cardiovascular risk factors. Our study provides evidence that genomic risk prediction for CHD has clinical utility in individuals aged 70 years and older.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01038583

Key Words: aspirin ◼ cardiovascular disease ◼ genetics ◼ prognosis ◼ risk factor

An increasing number of recent studies have suggested the potential clinical utility of using a polygenic risk score (PRS) to improve the prediction of coronary heart disease (CHD) events in the general population.1–8 It is now well established that adults with a high genetic risk score will have higher risk for CHD events, compared to those with a low score.3 Furthermore, the addition of a PRS has been shown to significantly...
Nonstandard Abbreviations and Acronyms

**ASPREE**  Aspirin in Reducing Events in the Elderly
**CHD**  coronary heart disease
**HDL**  high-density-lipoprotein
**PRS**  polygenic risk score

**RESULTS**

**Baseline Characteristics**

The median age of the 12,792 genotyped participants was 73.9 years (interquartile range 71.7–77.3, Table 1); 7027 (54.9%) were female, 391 (3.1%) were current smokers, and 1186 (9.3%) had diabetes. Comparing the 12,792 genotyped participants with nongenotyped participants of the ASPREE trial, we found only minor differences in baseline characteristics (Table S1 in the Supplemental Material). The PRS showed a normal distribution (Figure S3 in the Supplemental Material), and the mean value was −1.16 (SD, 0.45). There was no relevant correlation of the PRS with other continuous variables within the data set (Figure S4 in the Supplemental Material). In a multivariable linear regression model, the PRS was significantly associated with age, gender, systolic blood pressure, non–HDL cholesterol, HDL cholesterol, diabetes, and family history of MI (Table S2 in the Supplemental Material). During follow-up, 254 (2.0%) of genotyped participants had incident CHD events (169 in males, 85 in females). This included 226 incident cases of myocardial infarction and...

**Table 1. Baseline Characteristics**

| Overall population |
|--------------------|
| No. of participants | 12,792 |
| Age, median (IQR)  | 73.9 (71.7–77.3) |
| Age categories (%) | |
| 70–74               | 7698/12,792 (60.2) |
| 75–79               | 3271/12,792 (25.6) |
| 80–84               | 1414/12,792 (11.1) |
| >85                 | 409/12,792 (3.2) |
| Female (%)          | 7027/12,792 (54.9) |
| Current smoker (%)  | 391/12,792 (3.1) |
| Systolic blood pressure, mm Hg, mean (SD) | 139.46 (16.27) |
| Diastolic blood pressure, mm Hg, mean (SD) | 77.17 (9.97) |
| Diabetes (%)        | 1186/12,792 (9.3) |
| Body mass index, kg/m², mean (SD) | 27.97 (4.55) |
| HDL-c, mmol/L, mean (SD) | 1.59 (0.46) |
| Non–HDL-c, mmol/L, mean (SD) | 3.69 (0.93) |
| Fasting Glucose, mg/dL, mean (SD) | 98.29 (17.12) |
| Creatinine, mg/dL, mean (SD) | 0.90 (0.22) |
| Family history of MI (%) | 340/12,792 (2.7) |
| Polygenic Risk Score, mean (SD) | −1.16 (0.45) |

Missing values for continuous variables were: 341 for creatinine, 331 for non–HDL-c, 330 for HDL-c, 260 for fasting glucose, and 56 for body mass index. IQR indicates interquartile range, HDL-c, high-density lipoprotein cholesterol; and MI, myocardial infarction.
50 cases of CHD death. The incidence rate was 3.11 CHD events per 1000 person-years in PRS tertile 1, 4.29 CHD events per 1000 person-years in PRS tertile 2, and 4.97 CHD events per 1000 person-years in PRS tertile 3 (Table 2).

**PRS for Risk Prediction**

In the conventional model, all variables except systolic blood pressure and diabetes were found to be independent predictors of CHD events (Table 3). When the PRS was added as a continuous variable to the conventional model, it was found to be an independent predictor of outcome (hazard ratio [HR], 1.24 [95% CI, 1.08–1.42], \(P=0.002\)). The HR of the PRS per SD was comparable to that reported by 5 other published studies of younger adults where the same PRS was used (Table S3 in the Supplemental Material).

Using PRS tertiles as a predictor, CHD risk increased as the PRS category increased from the first to third tertile. When compared with the first PRS tertile (low-risk group) the second tertile had an HR for CHD risk of 1.48 (95% CI, 1.04–2.09, \(P=0.029\)) and the third PRS tertile had an HR of 1.64 (95% CI, 1.16–2.33, \(P=0.005\)). Kaplan-Meier curves illustrated that individuals in the higher and middle PRS tertiles had a higher incidence of CHD events compared with lower PRS tertile (\(P=0.02\), Figure 1). Furthermore, the continuous PRS was a significant predictor of outcome, when added to the SCORE2-OP risk model (HR, 1.24 [95% CI, 1.09–1.42], \(P=0.001\)).

Evaluation of each single predictor using receiver-operating-characteristics showed that sex (area under the curve [AUC], 62.88% [95% CI, 59.58–66.17]), HDL-cholesterol (AUC, 61.56% [95% CI, 57.51–65.61]), serum creatinine (AUC, 61.39% [95% CI, 57.53–65.24]), and age (AUC, 57.50% [95% CI, 52.98–62.05]) were the strongest predictors of incident CHD events (Figure 2). The PRS alone resulted in an AUC of 55.72% (95% CI, 51.74–59.72). The AUC for the conventional model was 70.53% (95% CI, 67.00–74.06) and significantly improved to 71.78% (95% CI, 68.32–75.24) after adding the PRS as a continuous variable (\(P=0.019\), Table 4, Figure S5 in the Supplemental Material). The calibration plot showed a good agreement between predicted and observed CHD events (Figure S6 in the Supplemental Material). The conventional model resulted in a categorical reclassification of 0.063 (95% CI, 0.001–0.129), with an upwards classification of 0.044 (95% CI, −0.007 to 0.105) and a downwards classification of 0.019 (95% CI, 0.003–0.032).

**Subgroup Analyses**

When comparing males and females, we only observed minor differences in baseline characteristics (Table S5 in the Supplemental Material). Adding the continuous PRS to the conventional model, it was an independent predictor in males, but not in females (males HR, 1.27 [95% CI, 1.08–1.50], \(P=0.005\) versus females HR 1.18 [95% CI, 0.92–1.49], \(P=0.19\), Tables S6 and S7 in the Supplemental Material). The same finding was observed when assessing the categorical PRS. The conventional model resulted in a lower AUC in males compared to females (males AUC, 66.58%, females AUC, 70.07%), but the incremental value of adding the PRS to the conventional model was greater in males compared with females (males AUC, 68.18%, females AUC, 71.00%, Table S8 in the Supplemental Material).

In subgroup analyses by PRS tertile, baseline characteristics were similar for participants within the highest compared to the lowest PRS tertile (Table S9 in the Supplemental Material). The conventional model resulted in a lower AUC in individuals from the highest, compared to individuals from the lowest PRS tertile (highest tertile AUC, 73.21%, lowest tertile AUC, 76.62%), but the incremental value of addition of the PRS to the conventional model was similar in both groups (Table S10 in the Supplemental Material).

Results of sensitivity analyses after adding use of antihypertensive drugs, statins, and genetic ethnicity principal component analyses to the model are reported in the supplemental results (Tables S11 and S12 in the Supplemental Material). Interaction effects between sex and model covariables were examined, but no interaction between sex and PRS was found (HR, 0.93 [95% CI, 0.69–1.24], \(P=0.60\); Table S13 in the Supplemental Material).

**Table 2. Incidence Rate of CHD Events Per PRS Tertiles**

| PRS tertile | N  | CHD events | Incidence rate per 1000 person-years |
|-------------|----|------------|-----------------------------------|
| 1           | 4263 | 56       | 3.11                               |
| 2           | 4264 | 77       | 4.29                               |
| 3           | 4264 | 88       | 4.97                               |

CHD indicates coronary heart disease; and PRS, polygenic risk score.
Finally, we investigated the interaction of aspirin treatment (as per ASPREE randomization) with the PRS but did not find a significant interaction (P=0.58, Table S14 in the Supplemental Material).

**DISCUSSION**

In this study, we evaluated the prognostic value of a previously derived polygenic risk score (metaGRS) to predict future CHD events in a population of healthy older individuals from the ASPREE trial. We demonstrated robust PRS performance in this older population and can confirm that addition of the PRS to a conventional cardiovascular risk model improved risk prediction (Figure 3). Our study suggests that the potential clinical utility of a PRS for CHD riskprediction extends to older individuals aged 70 years and older, who comprise an important high-risk group. Our study also represents an independent validation of a recently derived PRS, in a well-characterized older population. Our findings add further support to the growing body of evidence that supports the use of genomic risk information to improve CHD risk prediction, and our results indicate that the prognostic value of a genomic risk score for CHD extends to older individuals, who comprise an important high-risk group.

The metaGRS used in our study was derived using data from a range of different CHD studies from younger adult populations, then validated in the UK Biobank population of around 500,000 British individuals, with mean age of 56.5 years. The score has since been validated in a range of other external validation studies of younger adult

---

### Table 3. HRs for the Conventional Model, Conventional Model+Continuous PRS, and Conventional Model+Categorical PRS

|                     | Conventional model | Conventional model+continuous PRS | Conventional model+categorical PRS | SCORE2-OP+continuous PRS |
|---------------------|-------------------|---------------------------------|----------------------------------|--------------------------|
| Age                 | 1.09 (1.06–1.12)  | <0.001                          | 1.09 (1.06–1.12)                 | <0.001                   |
| Female sex          | 0.48 (0.34–0.67)  | <0.001                          | 0.46 (0.33–0.65)                 | <0.001                   |
| Current smoking     | 2.00 (1.09–3.68)  | 0.025                           | 2.02 (1.10–3.71)                 | 0.024                    |
| SBP per 10 mmHg increase | 1.04 (0.96–1.13) | 0.34                            | 1.04 (0.96–1.13)                | 0.37                     |
| Non–HDL-c           | 1.35 (1.17–1.56)  | <0.001                          | 1.35 (1.17–1.56)                 | <0.001                   |
| HDL-c               | 0.65 (0.44–0.95)  | 0.028                           | 0.65 (0.44–0.95)                 | 0.027                    |
| Diabetes            | 0.82 (0.49–1.38)  | 0.45                            | 0.81 (0.48–1.36)                 | 0.42                     |
| Creatinine          | 1.83 (1.03–3.26)  | 0.040                           | 1.81 (1.01–3.23)                 | 0.045                    |

HDL-c indicates high-density lipoprotein cholesterol; HR, hazard ratio; PRS, polygenic risk score; SBP, systolic blood pressure; and SCORE2-OP, Systematic Coronary Risk Evaluation 2-Older People.

---

**Figure 1.** Kaplan-Meier curve for coronary heart disease (CHD) events according to polygenic risk score (PRS) tertiles.

The figure provides the probability of a CHD event according to tertiles of the PRS, based on Kaplan-Meier estimates, and the individuals at risk.
The ASPREE population differs in several aspects. First, and most notably, the median age of ASPREE participants at enrollment was far older at 73.9 years, nearly 20 years older than the UK Biobank. Yet, the HR of the PRS remained similar. Second, ASPREE is a highly ascertained clinical trial population, in which participants met strict inclusion criteria, with no history of CHD events at enrollment. Third, major CHD events in ASPREE were adjudicated as part of a randomized trial but did not include coronary revascularization. Given these important differences, it is noteworthy that the metaGRS still performed in a robust manner in the older ASPREE population, with similar HR and AUC compared with studies of younger populations. Similar to previous studies, our findings demonstrate a polygenic model derived from the UK Biobank generalizes well to other cohorts of European ancestry.

CHD accounts for a large proportion of deaths in older people. Accurate identification of older individuals at increased risk for CHD is, therefore, clinically important, particularly those not identified as high-risk by conventional risk factors. Due to a lack of evidence in individuals aged 70 years and older, the value of adding genetic information for CHD risk prediction in older people has not previously been tested robustly. Our study, therefore, provides the first evidence of its kind to suggest the predictive value and potential clinical utility of a PRS for CHD extends to individuals aged 70 years and older. We observed comparable predictive performance of the PRS versus younger population-based cohorts and demonstrated that addition of the PRS to a conventional risk factor model we constructed, and to the recently derived SCORE2-OP clinical risk model, improved prediction.

### Table 4. Categorical Net Reclassification Improvement Table After Adding PRS to the Conventional Model to Predict the Risk of a 5-Year CHD Event

|                      | Standard model | Standard model+polygenic risk score | Total no. (%) of participants |
|----------------------|----------------|-----------------------------------|------------------------------|
|                      |                | <1.5%  | 1.5 to 2.49% | ≥2.5%         |                           |
| CHD events   |                | 37     | 9         | 0          | 46 (22)                  |
| <1.5%       | 6             | 35     | 12        | 53 (25)    |
| 1.5%–2.49% | 0             | 8      | 103       | 111 (53)   |
| ≥2.5%      | 43 (20)       | 52 (25)| 115 (55)  | 210 (100)  |
| Total no. (%) of participants | 2453 (50) | 1198 (24) | 1265 (26) | 4916 (100) |
| CHD nonevents | 1176 (25) | 187     | 1302 (26) | 1302 (26)  |
Neumann et al. PRS for Coronary Heart Disease

Circ Genom Precis Med. 2022;15:e003429. DOI: 10.1161/CIRCGEN.121.003429 February 2022 31

Notably, we found that the PRS alone (considered independently as a CHD risk factor) had similar discriminative power compared to conventional CHD risk factors used in routine practice. However, in our analyses, the AUC of sex, HDL-cholesterol, creatinine, non–HDL-cholesterol, and age were stronger discriminators than the PRS alone. This emphasizes the importance of these risk factors as predictors in an older population, alongside a genetic risk score. Nevertheless, it is noteworthy that the PRS was found to predict CHD events independently of conventional risk factors, not showing correlation with the nine conventional risk factors examined (Figure S4 in the Supplemental Material). These unique properties of the genetic risk score (ie, relatively strong predictive performance and independent effect) help demonstrate its future clinical potential for CHD risk prediction in populations of older adults.

Currently, the availability of PRS as a clinical tool for CHD prediction at large remains limited, with unresolved questions related to cost-effectiveness and implementation. Furthermore, some recent studies have provided conflicting results regarding the incremental value of adding genetic information to conventional CHD risk factors in younger populations. Although the magnitude of improved CHD risk prediction achieved by the PRS may be small or incremental in an individual study, when the effects are extrapolated to a far larger population (eg, an entire country, comprising millions of older adults), effects are substantial. In the future, individual genotyping will become more widely available and at lower cost, potentially facilitating improved CHD event prediction and risk stratification at the population level. Here, we show that genetic risk is still highly relevant at older ages and that a PRS for CHD still performs well, and may have potential clinical utility for preventive strategies in older people. However, further studies of more phenotypically and ethnically diverse elderly populations are required to generalize these results.

Specific findings of our study warrant further discussion. First, we did not find diabetes to be an independent predictor for CHD events, despite 9.3% of ASPREE participants having diabetes at baseline. Other studies have reported the relevance of diabetes regarding CHD risk in the elderly. This observation could be explained by the preselection of a healthy ASPREE population, in whom the duration of diabetes might be shorter, compared to the general population. A second notable finding of our study was that results were not confirmed in subgroup analyses for females. This finding was likely due to limited power because the majority of CHD events in ASPREE occurred in males. Further, we found no interaction effect between sex and PRS, and other studies have reported similar performance for CHD polygenic scores in both sexes. Third, we investigated the interaction of aspirin treatment with the metaGRS in exploratory analyses but found no significant interaction (P=0.58). This suggested that in the ASPREE trial, participants with a high CHD PRS did not benefit more from low-dose aspirin use, versus participants with a low PRS, for primary prevention of CHD events. Further studies are required to determine whether other genotypic sub-sets of the population may benefit from aspirin use.

Strengths of our study include a well-characterized, unique study population with incident cardiovascular events clinically adjudicated as part of a randomized trial. No other large clinical trial has recruited this number of healthy older individuals without a prior history of CHD events, with genotyping. All ASPREE participants received medical assessments by general practitioners.
at enrollment to confirm eligibility for the trial, and to rule out previous diagnoses of CHD events. This provided confidence that participants were CHD event-free at enrollment to examine the value of PRS in the context of primary prevention in the elderly. A range of conventional risk factor variables were also available in ASPREE to examine alongside polygenic risk.

Limitations of our study include a rather short follow-up period (average 4.6 years per participant) contributing to the relatively small number of CHD events. Continued follow-up will provide more power for future analyses. We also acknowledge the potential healthy-volunteer effect (ascertained bias) and survivorship bias of the ASPREE trial population. ASPREE did not collect information related to revascularization, which is an important CHD end point used in metaGRS derivation dataset. Our findings may not be generalizable to other ancestries or more diverse populations.

In conclusion, we report a potential clinical benefit of using a PRS for improved risk prediction of CHD events in older people. Our study provides some of the first evidence that use of PRS for CHD prediction is robust across a diverse range of populations and age groups, including individuals aged 70 years and older which are a distinct high-risk group.

ARTICLE INFORMATION
Received March 4, 2021; accepted October 26, 2021.

Affiliations
Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia (J.T.N., MR, A.B., GP, L.T.P.T., M.R.N., R.L.W., C.M.R., A.M.T., J.M., P.L.). Department of Cardiology, University Heart & Vascular Centre, Hamburg, Germany (J.T.N.). German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg (J.T.N.). Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (M.R.N.). Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (G.A.M.). Department of Public Health and Primary Care, University of Cambridge, United Kingdom (M.I.). School of Public Health, Curtin University, Perth, WA, Australia (C.M.R.).

Acknowledgments
We thank the ASPREE trial (Aspirin in Reducing Events in the Elderly) staff, participants, and general practitioners, and the Ramaciotti Centre for Genomics.

Sources of Funding
The trial was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (grant numbers U01AG009824 and U19AG006262); the National Health and Medical Research Council (NHMRC) of Australia (grant numbers 334047 and 1127062); Monash University and the Victorian Cancer Agency. Genotyping supported by Bioplatforms Australia, National Framework Initiative (2018-2020). Dr Neumann is recipient of a fellowship by the Deutsche Forschungsgemeinschaft (NE 2156/1–1). Dr Reid is supported through a NHMRC Principal Research Fellowship (APP 1136372). Dr Lacaze is supported by a National Heart Foundation Future Leader Fellowship (102604).

Disclosures
None.

Supplemental Materials
Supplemental Material
Supplemental Results
Tables S1–S14
Figures S1–S6

REFERENCES
1. Marenberg ME, Risch N, Berkman LF, Fidlerus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study in twins. N Engl J Med 1994;330:1041–1046. doi: 10.1056/NEJM199404133010503
2. Lloyd-Jones DM, Nallamothu BK, D’Agostino RB Sr, Levy D, Murabito JM, Wang TY, Wilson PW, O’Donnell CJ. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004;291:2204–2211. doi: 10.1001/jama.291.18.2204
3. Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med 2018;378:2349–2358. doi: 10.1056/NEJMoa1605086
4. Inouye M, Abraham G, Nelson CP, Wood AM, KottkeTF, Udribe F, Lai FY, Kaptoge S, Groenwegen M, Wang T, et al; UK Biobank Cardiovascular Bolic Consortium CHD Working Group. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol 2018;72:1883–1983. doi: 10.1016/j.jacc.2018.07.079.
5. Wünnemann F, Sin Lo K, Langford-Avelar A, Busseuil D, Dubé MP, Tardif JC, Lettge G. Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians. Circ Genom Precis Med. 2019;12:e002481. doi: 10.1161/CIRCGEN.119.002481
6. Dikilitas O, Schaad DJ, Kosel ML, Carroll RJ, Chute CG, Denny JA, Fedotov A, Feng Q, Hakonarson H, Jarvik GP, et al. Predictive utility of polygenic risk scores for coronary heart disease in three major racial and ethnic groups. Am J Hum Genet 2020;106:707–716. doi: 10.1016/j.ajhg.2020.04.002.
7. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM, Dehghan A, Moller DC, Elliott P, Zoufaki I. Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease. JAMA 2020;323:636–645. doi: 10.1001/jama.2020.22241
8. Mosley JD, Gupta DK, Tan J, Yao J, Wells GS, Shaffer CM, Kundu S, Robinson-Cohen C, Psaty BM, Rich SS, et al. Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease. JAMA 2020;323:627–635. doi: 10.1001/jama.2019.21782
9. Aragam KG, Dobbsn A, Judy R, Choffin M, Chaudhary K, Hindy G, Cagan A, Finneran P, Weng LC, Loos RUF, et al. Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease. J Am Coll Cardiol 2020;75:2769–2780. doi: 10.1016/j.jacc.2020.04.027
10. Timmerman N, de Klein J, van der Heijden RA, van der Vlist P, Klaassen B, van der Laan SW. Family history and polygenic risk of cardiovascular disease: Independent factors associated with secondary cardiovascular events in patients undergoing carotid endarterectomy. Atherosclerosis. 2020;307:121–129. doi: 10.1016/j.atherosclerosis.2020.04.013
11. Gladstone PA, Leggett M, Falkein D, Larsen P, Doughty R. Polygenic risk scores in coronary artery disease and atrial fibrillation. Heart Lung Circ. 2020;29:634–640. doi: 10.1016/j.hlc.2019.12.004.
12. Dalton JE, Rothenberg MB, Dawson NV, Krieger NI, Zidar DA, Perzynski AT. Failure of traditional risk factors to adequately predict cardiovascular events in older populations. J Am Geriatr Soc. 2020;68:754–761. doi: 10.1111/jgs.16329
13. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. doi: 10.1016/S0195-668X(03)00114-3.
14. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, De Bakker PIW, Farquharson A, Ferrante M, Fuster V, et al; European Society of Cardiology Task Force on Cardiovascular Disease Prevention and Rehabilitation. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2351–2381. doi: 10.1093/eurheartj/ehw256.
15. group SOW and collaboration ESCGr. SCORE2-DP risk prediction algorithm: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42:2455–2467. 10.1093/eurheartj/ehab312
16. Lu T, Forgetta V, Yu OHY, Mokry L, Gregory M, Thanassoulis G, Greenwood CMT, Richards JB. Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes. Cardiovasc Diabetol 2020;19:12. doi: 10.1186/s12939-020-0988-9